Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma

Brian Lipworth (Lead / Corresponding author), Chris RuiWen Kuo, Kirsten Stewart, Rory Chan

Research output: Contribution to journalArticlepeer-review

Abstract

Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.

Original languageEnglish
Number of pages4
JournalJournal of Allergy and Clinical Immunology: In Practice
Early online date11 Dec 2023
DOIs
Publication statusE-pub ahead of print - 11 Dec 2023

Keywords

  • asthma
  • airway hyperresponsiveness
  • biologic
  • remission
  • Remission
  • Airway hyper-responsiveness
  • Biologic
  • Asthma

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma'. Together they form a unique fingerprint.

Cite this